5-Bromo-2-methoxyquinoline-8-carbaldehyde, 95.0%, 1g

2-Amino-4,6-dibromopyrimidine, 95.0%, 10g

Ethyl 3,3-diphenylpropanoate, 97%, 5g

(4-Aminophenyl)dimethylphosphine oxide hydrochloride, 95.0%, 1g

1-(5-(Dimethylphosphoryl)thiophen-2-yl)ethanone, 98%, 250mg

(4-(Phenylcarbamoyl)phenyl)boronic acid, 95.0%, 1g

Methyl 3-amino-5-iodo-2-methylbenzoate, 1g

2-(Dimethoxymethyl)-1,6-naphthyridine, 95.0%, 1g

tert-Butyl (3aR,6aR)-3a-(hydroxymethyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate, 95%, 250mg

N,N-Diisopropylethylamine (DIPEA), 100mL, >=99.5%, for peptide synthesis, glass packaging

Tazarotenic acid, 99.57%, 250mg

(R)-Isopropyl pyrrolidine-2-carboxylate hydrochloride, 5g

6-ethoxy-N-(furan-2-ylmethyl)benzo[d]thiazol-2-amine, 95.0%, 1g